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Abstract
Background: The EQ-5D has been extensively used to assess patient utility in trials of new treatments within the
cardiovascular field. The aims of this study were to review evidence of the validity and reliability of the EQ-5D, and
to summarise utility scores based on the use of the EQ-5D in clinical trials and in studies of patients with
cardiovascular disease.
Methods: A structured literature search was conducted using keywords related to cardiovascular disease and EQ-
5D. Original research studies of patients with cardiovascular disease that reported EQ-5D results and its
measurement properties were included.
Results: Of 147 identified papers, 66 met the selection criteria, with 10 studies reporting evidence on validity or
reliability and 60 reporting EQ-5D responses (VAS or self-classification). Mean EQ-5D index-based scores ranged
from 0.24 (SD 0.39) to 0.90 (SD 0.16), while VAS scores ranged from 37 (SD 21) to 89 (no SD reported). Stratification
of EQ-5D index scores by disease severity revealed that scores decreased from a mean of 0.78 (SD 0.18) to 0.51 (SD
0.21) for mild to severe disease in heart failure patients and from 0.80 (SD 0.05) to 0.45 (SD 0.22) for mild to severe
disease in angina patients.
Conclusions: The published evidence generally supports the validity and reliability of the EQ-5D as an outcome
measure within the cardiovascular area. This review provides utility estimates across a range of cardiovascular
subgroups and treatments that may be useful for future modelling of utilities and QALYs in economic evaluations
within the cardiovascular area.
Background
Cardiovascular disease (CVD) imposes a great burden
on societies around the world, with an estimated 16.7
million - or 29.2% of total global deaths - resulting from
various forms of CVD[1]. A recent study estimated the
total costs of CVD in the European Union, in terms of
health care expenditure and lost productivity, to be
€169bn a year [2]. Major CVDs include coronary heart
disease (CHD), cerebrovascular disease, hypertension
and heart failure. In addition, CVD has a significant
impact on health-related quality of life (HRQoL) in
patients who survive coronary events such as heart
attacks (myocardial infarction) or stroke. It has been
suggested that HRQoL measures (i.e. measures that
refer to a patient’s emotional, social and physical well-
being) are particularly useful with respect to
investigating treatment of CVD in three instances: 1)
when results of clinical trials show little evidence of a
major improvement in survival so that choice of therapy
will be determined on the basis of quality of life mea-
surement; 2) when a treatment is effective in reducing
mortality, but has toxic or unacceptable side effects so
that quality of life measurement may help physicians
and their patients weight the benefits and risks of such
a treatment; 3) when patients are asymptomatic or have
mild symptoms, the morbidity and mortality rates are
low, and the therapy is long term[3].
Increasingly over time, clinical trials within the cardio-
vascular field have included HRQoL measures. Such mea-
sures, alongside clinical measures of functionality, can
help evaluate the physical, mental and emotional implica-
tions of CVD as well as the effects of surgical and medical
treatments. Commonly used functional classification sys-
tems within the cardiovascular field are the New York
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for heart failure patients and the Canadian Cardiovascular
Society (CCS) grading scale for angina pectoris[4,5].
HRQoL measurement in CVD can be assessed using dis-
ease-specific instruments such as the Seattle Angina Ques-
tionnaire (SAQ); MacNew Heart Disease Health-related
Quality of Life Questionnaire; and the Minnesota Living
with Heart Failure score (MLHF) [6-8]. These question-
naires are particularly sensitive to changes in aspects of
HRQoL directly related to CVD. Alternatively, commonly
used generic measures of HRQoL including the SF-6D,
Health Utilities Index (HUI) and the EQ-5D have also
been used in CVD studies [9-11]. The main advantages of
such generic multi-attribute health state classifiers are that
they allow the calculation of Quality adjusted life years
(QALYs) within cost-utility analyses as well as allowing
comparison of HRQoL across different conditions and
against age-sex matched population norms.
Among the available generic measures, the EQ-5D has
gained widespread use due to its simplicity to adminis-
ter, score and interpret. It also imposes minimal burden
on the respondent as it is a brief, simple measure for
patients to understand and to complete. The index-
based score is generated by applying societal preference
weights to the health state classification completed by
the patient that consists of five dimensions (mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression), each with three levels of response or sever-
ity (no problems, some problems, or extreme problems).
The ability to convert self classification responses into a
single index score makes the EQ-5D practical for clini-
cal and economic evaluation[11]. The index-based score
is typically interpreted along a scale where 1 represents
best possible health and 0 represents dead, with some
health states valued as being worse than dead (<0). In
addition to the index-based scoring system, the visual
analogue scale (VAS) component of the EQ-5D enables
the patient to place their current health state on a range
from 0 (worst imaginable health state) to 100 (best ima-
ginable health state). Algorithms have been developed
based on societal preferences for health states, with the
most popular being based on the UK-based population
[12], although many other country-specific algorithms
are also available [13-18].
The principle aims of this paper were: to synthesise
the evidence on the validity and reliability of the EQ-5D
in studies within the cardiovascular field; to summarise
the EQ-5D based scores reported in studies within the
CVD field; and to attempt to stratify mean utility scores
according to level of disease severity.
Methods
Data Collection and Assessment
A computerised search of the current published litera-
ture was performed using MEDLINE and EMBASE for
the period January 1988 to October 2008. The search
strategy combined exploded or medical subject headings
relating to the CVD field and the EQ-5D as follows:
(’cardiovascular’/exp OR ‘cardiovascular’) OR (’cardiac’/
exp OR ‘cardiac’) OR (’cardiology’/exp OR ‘cardiology’)
AND ‘euroqol’ OR ‘EQ 5D’ OR ‘EQ5D’. The EuroQol
website http://www.euroqol.org was also used to identify
unique references, including working papers and confer-
ence proceedings that may not have been captured in
the initial literature search. Only full-text published
papers were included for analysis.
The inclusion criteria required that the paper was ori-
ginal research, and that it reported EQ-5D scores speci-
fic to cardiovascular disease or reported psychometric
properties of the EQ-5D in a population with cardiovas-
cular disease. Studies that only reported EQ-5D index or
VAS scores graphically in terms of change over time
were excluded from the analysis. When multiple studies
used the same dataset, EQ-5D scores were only reported
from one article to avoid double counting. No language
restrictions were imposed. Study abstracts that poten-
tially met the inclusion criteria were identified, and full-
text articles were retrieved for further review. A stan-
dard data abstraction form was developed to facilitate
the structured review, which included study design,
patient characteristics, intervention information, pub-
lished source of index-based preference weights and
EQ-5D scores as well as details of any other clinical
measures; disease-specific quality of life and generic
HRQoL instruments. A summary of the results of the
literature search is provided in figure 1.
Data Analysis
Initially, studies that reported EQ-5D index-based
scores and/or VAS scores were sorted into cardiovas-
cular subgroups (e.g. Angina/Myocardial Infarction/
CHD etc) that were informed by the latest WHO
International Classification of Diseases (ICD-10: I00-
I99 - diseases of the circulatory system) (Table 1 in
Additional file 1) [19]. Confidence intervals were calcu-
lated from the sample size and standard deviation (SD)
or the standard error when not reported directly in the
paper. Scores that were not reported using the appro-
priate range of scale were transformed, i.e. index-based
scores anchored by 0 (dead) and 1 (full health), VAS
scores range from 0 (dead) to 100 (full health). If EQ-
5D results were stratified (e.g. by age, sex and disease
severity), results were only reported once, using the
most clinically relevant stratification: CCS angina clas-
sification; NYHA heart failure classification or demo-
graphic characteristics (% of males/females and mean
age of patient cohort). Error bars in Figures 2 and 3
represent 95% confidence intervals around the mean
score, which were calculated from the reported SD and
sample size. There was no attempt to combine
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estimates from different studies in a formal meta-ana-
lysis since the main objective was to contrast studies
with different features and to explain heterogeneity in
the results. The degree of heterogeneity between stu-
dies was quantified using the I2 statistic [20]. The I2
statistic uses the sum of the squared differences of
each study from the pooled estimate and the degrees
of freedom of the test to provide a measure of the per-
cent of total variation across studies due to heteroge-
neity between studies. A meta-analysis yielding a value
of I2 above 75% suggests a high level of heterogeneity
between the studies. Psychometric properties were
summarised according to the type of property assessed
(validity/reliability/responsiveness), the comparison
performed, and the statistical test result.
Results
The electronic search of databases returned 147 papers
of which 66 met the selection criteria. 60 publications
reported an EQ-5D index score, VAS score and/or
responses to the self-classification system, whilst 10
papers presented evidence of the psychometric proper-
ties of the EQ-5D (Figure 1).
Overall, there was wide variation in terms of CVD
subgroups, disease stage, age distribution and other
methodological aspects (Table 1 in Additional file 1). Of
studies reporting mode of administration (n = 41), 42%
were filled out on-site by respondents, 52% were
mailed-out questionnaires, and 6% were administered
via telephone interview. Overall, there was an equal mix
of randomised controlled trial (RCT) and observational
study designs. Prospective observational study designs
were more common than retrospective (69% vs. 31%)
and there was an equal mix of longitudinal and cross-
sectional studies. The majority of studies (52%) reported
EQ-5D index scores using the UK-based algorithm
although scores based on Czech, Danish, Dutch, Ger-
man, US and European preferences were also used
[13-18]. However, a number of studies (33%) did not
explicitly state the algorithm used to calculate the index
score.
Studies of cardiovascular patients that reported psy-
chometric properties of the EQ-5D (n = 10) explored
construct validity (convergent and discriminative), typi-
cally in terms of correlations with other disease-specific
HRQoL measures as well as reliability and
Figure 1 Summary of literature search.
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Figure 2 EQ-5D Index Mean scores for Heart Failure patients - Stratified by baseline disease severity (NYHA class).
Figure 3 EQ-5D Index Mean scores for IHD patients - Stratified by baseline disease severity (CCS class).
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responsiveness (Table 2 in Additional file 1). Evidence of
validity and reliability were reported in studies of ischae-
mic heart disease (n = 3); cerebrovascular disease (n =
3); heart failure (n = 2) and peripheral vascular disease
(n = 2). Convergent validity was the most common
property assessed, using Spearman rank correlations to
explore associations with another measure. Reliability
and responsiveness were generally measured by test-ret-
est statistics; intra-class correlation coefficients (ICC)
and effect size (ES). In terms of construct validity, com-
parisons were made between the EQ-5D and disease
specific questionnaires such as the Barthel Index (BI),
Kansas City Cardiomyopathy Questionnaire (KCCQ),
MacNew Heart Disease Quality of Life Questionnaire,
NYHA and VascuQol as well as other generic measures
such as the Health Utilities Index (HUI2; HUI3) and the
RAND Short Form Health Survey (SF-36) and its deriva-
tives (SF-6D; SF-12;).
For convergent validity, moderate to strong agreement
represented as significant correlation was generally
found between EQ-5D Index and VAS scores and other
generic HRQoL measures both at the domain and index
level [21-23]. For discriminative validity, the EQ-5D was
less able to detect clinical changes than other disease
specific measures such as the KCCQ or NYHA and per-
formed better when detecting large rather than small
changes in disease severity [24]. There was also evidence
of strong ceiling effects (i.e. inability to discriminate
between comparatively good health states) across both
domain and index values [21,25]. In general, the EQ-5D
Index and VAS showed good reliability and responsive-
ness in comparison to other generic measures such as
the SF-12 but were less responsive than disease-specific
measures such as the KCCQ [26,27].
A wide range of mean and median EQ-5D scores were
reported (Table 3 in Additional file 1). Studies of
patients with ischaemic heart diseases (ICD codes I20-
I25) reported mean index scores that ranged from 0.45
(SD 0.22) to 0.88 (no SD reported). Visual analogue
scale (VAS) scores ranged from a mean of 45 (SD 17) to
82 (SD 13). Studies of heart failure (I50) patients
reported mean index scores ranging from 0.31 (no SD)
to 0.78 (0.11) and mean VAS scores from 37 (21) to 73
(18). Studies of cerebrovascular diseases (I60-I69)
reported mean index scores ranging from 0.24 (0.39) to
0.90 (0.16) and mean VAS scores from 51 (SD 20) to 89
(no SD). Studies of peripheral vascular diseases (I73)
reported mean index scores ranging from 0.33 (no SD)
to 0.78 (0.23) and mean VAS scores ranging from 49
(no SD) to 71 (8).
The lowest mean EQ-5D index scores were reported
in female patients with intermittent claudication under-
going secondary amputation [28]; patients with a large
deterioration in heart failure [24]; and post-stroke
patients [29] (Table 3 in Additional file 1). The highest
mean EQ-5D index scores were reported in elderly
CHD patients one year after undergoing exercise train-
ing [30]; post-trans-ischaemic attack (TIA) patients at
four-year follow-up [31] and patients with history of
subarachnoid haemorrhage [32].
An attempt was made to stratify mean EQ-5D index
or VAS scores by disease severity (for example by CCS
angina grading scale or NYHA heart failure classifica-
tion). Both the CCS and NYHA scales range from class
I (mild symptoms) to class IV (severe symptoms) and
CCS can also be graded as 0 for no symptoms (Table
4 in Additional file 1). A previously published study
stratified mean EQ-5D scores across CCS grades for
patients with stable angina [33]. The results showed
mean EQ-5D scores decreasing as the severity of
angina increased. EQ-5D index scores ranged from
0.36 (95% CI: 0.25 to 0.48) for CCS grade IV to 0.81
(95% CI: 0.77 to 0.85) for CCS grade 0. Here, there
was sufficient data available to stratify mean EQ-5D
index scores by NYHA class in heart failure patients
and by CCS class in patients with ischaemic heart dis-
ease (IHD). EQ-5D index scores were stratified into
three categories of NYHA or CCS class based on the
percentage of patients in a given group in a study in
class III/IV (0-33%; 34-67%; 68-100%). It was assumed
here that 0-33% in class III/IV corresponds to mild
HF/angina whilst 68-100% corresponds to moderate/
severe HF/angina.
In almost all cases, mean EQ-5D index scores
increased with an increase in the proportion of patients
with mild disease (Figure 2). Mean EQ-5D index scores
decreased from 0.78 (SD 0.18) for mild states to 0.51
(SD 0.21) for moderate/severe health states. In common
with heart failure patients, mean EQ-5D index scores
for IHD patients generally decreased with the increasing
proportions of patients with moderate/severe angina
(Figure 3). Here, scores decreased from a mean of 0.80
(SD 0.05) for mild angina to 0.45 (SD 0.22) for moder-
ate/severe angina.
An initial attempt was made to summarise the burden
of CVD for each disease subgroup by calculating pooled
means across studies. Both fixed and random effects
meta-analyses were carried out for studies that used
reported EQ-5D index scores and disease severity in
terms of either CCS Angina class or NYHA heart failure
class at baseline. Fixed and random effects meta-ana-
lyses of heart failure patients stratified by NYHA class
and IHD patients stratified by CCS angina class pro-
duced I2 indices of between 82-96%, suggesting a high
level of statistical heterogeneity between studies [34].
Such a degree of heterogeneity between studies ruled
out any further estimation of pooled mean utility scores
according to disease severity.
Dyer et al. Health and Quality of Life Outcomes 2010, 8:13
http://www.hqlo.com/content/8/1/13
Page 5 of 12
14 studies also provided detailed information on the
dimension-specific burden of cardiovascular disease,
exploring the distribution of scores across the five
dimensions of the EQ-5D [21,23,35-46]. In examining
the dimension-specific burden of disease among cardio-
vascular studies, the trend in the distribution of scores
was fairly similar across all five dimensions. In general,
problems with usual activities tended to be most com-
mon, followed by problems with mobility and pain/dis-
comfort (Figures 4, 5, 6, 7 and 8).
Discussion
In recent years use of the EQ-5D to measure patient
HRQoL in published studies within the cardiovascular
field has increased. This largely reflects the growing
requirement, over time, of clinical trials to consider
cost-effectiveness alongside the clinical effectiveness of
new interventions. As the “gold standard” form of eco-
nomic evaluation in many health care systems, cost-uti-
lity analyses (CUA) rely on generic measures such as
the EQ-5D for the calculation of QALYs. Increased use
of the EQ-5D may also support the view that patient
reported outcomes and quality of life are becoming
more widely accepted as routine measures in clinical
studies, with the EQ-5D being an internationally recog-
nised generic measure of HRQoL. This summary of EQ-
5D index and VAS scores in the cardiovascular field
complements other published reports describing the use
of the EQ-5D in the cancer and asthma/COPD literature
and of utility scores associated with various conditions
[47-50].
The review found that the majority of studies that
included the EQ-5D were within IHD (I20 - I25) and
cerebrovascular disease (I60 - I69), subgroups, reflecting
the relative prevalence of these diseases worldwide. Stra-
tification by disease severity (measured by CCS angina
or NYHA heart failure scales) was possible for IHD
patients and heart failure patients and illustrated a posi-
tive relationship with the EQ-5D when moving from
severe to mild disease severity (Figures 2 and 3). How-
ever, calculation of pooled means across studies using
meta-analytic techniques was not appropriate, given the
high level of heterogeneity in terms of study design and
patient characteristics. In general, evaluations of the
validity and reliability of the EQ-5D suggested fairly
strong convergent validity when assessed by correlations
with other HRQoL measures and good discriminative
abilities in detecting patients whose health status chan-
ged by a given clinical magnitude. However, there was
evidence of strong ceiling effects across each domain for
the index values. In terms of the dimension-specific bur-
den of cardiovascular disease, problems with pain or dis-
comfort were the most common, followed by problems
with usual activities and mobility.
There was much heterogeneity in the scores observed
across the studies, which was not necessarily entirely
Figure 4 Distribution of Scores for Mobility Dimension of EQ-5D.
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explained by the range of cardiovascular subgroups. The
diverse range of index and VAS scores was also related
to stage of illness or treatment (for example baseline
versus post-treatment measurements) as well as non-dis-
ease-related factors such as other co-morbidities and
demographic characteristics. Furthermore, no a priori
quality criteria were imposed on studies included for
review in terms of sample size or methodological quality
which may explain some of the heterogeneity. On the
other hand, imposing stringent inclusion criteria in
terms of study methodological quality would have
reduced the potential availability of studies considered
for analysis. It is difficult to predict to what extent the
level of heterogeneity would have been reduced if more
stringent inclusion criteria had been imposed for the lit-
erature review.
Figure 5 Distribution of Scores for Self-Care Dimension of EQ-5D.
Figure 6 Distribution of Scores for Usual Activities Dimension of EQ-5D.
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Overall, this study illustrated the difficulty in attempt-
ing to adequately deal with statistical heterogeneity
based on aggregated data from published studies [51].
This would suggest that individual patient-level data is
required in order to estimate mean utility scores accord-
ing to disease stage, at least within the cardiovascular
field. Furthermore, not all studies used the same algo-
rithm to calculate index-based scores with a third of
studies also failing to report which scoring system was
used. The choice of algorithm used to convert self-clas-
sification scores can affect the index-based score, as
shown in a recent study which compared UK and US
scoring algorithms in patients undergoing percuatenous
coronary intervention (PCI) [52]. However, whilst coun-
try-specific societal preferences may reduce the scope
for comparing HRQoL estimates across studies from
Figure 7 Distribution of Scores for Pain/Discomfort Dimension of EQ-5D.
Figure 8 Distribution of Scores for Anxiety/Depression Dimension of EQ-5D.
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different countries, they are more helpful to local deci-
sion making, especially when allocating resources within
national health care programmes.
Conclusion
HRQoL measures such as the EQ-5D can be useful tools
to clinicians in terms of evaluating the impact of cardio-
vascular disease on patients and can help to inform
decision making and resource allocation. The use of the
EQ-5D in CVD studies has increased in recent years
and published studies provide evidence of its validity
and reliability. The variation in EQ-5D index and VAS
scores reported here largely reflect systematic differ-
ences in terms of disease stage, treatment and patient
characteristics. In the future, as more studies of CVD
present EQ-5D scores according to disease severity, it
may be possible to calculate pooled mean estimates that
can be useful in modelling of CVD-related health out-
comes in economic evaluations.
Abbreviations used in Tables/Figures
AAA: Abdominal aortic aneurysm; ACS: Acute coronary
syndromes; ACT: Anticoagulation therapy; AF: Atrial
fibrillation; AH-Drug: Anti-hypertensive drug therapy;
AHF: Advanced heart failure; AMI: Acute myocardial
infarction; Amp.: Amputation; Angio: Coronary Angio-
graphy; ASA: American Society of Anaesthesiologists;
ASCOT-AHD: Anglo-Scandinavian cardiac outcomes
trial - anti-hypertensive drug treatment; Asym./Sym.:
Asymptomatic/Symptomatic; AUT: Austria; AVR: Aortic
valve replacement; BI: Barthel Index; BOTH-CABG/
PCI/MM: Patients who are suitable for both CABG and
PCI and receive CABG/PCI/MM; CABG: Coronary
artery bypass graft; CABG-80: Coronary artery bypass
surgery in octogenarians; CABG-CABG/PCI/MM:
Patients who are suitable for CABG and receive CABG/
PCI/MM; CABG-CPB: CABG using heart lung machine;
CAD: Coronary artery disease; C-Arrest: Cardiac arrest;
CCR: Comprehensive cardiac rehabilitation; CCS: Cana-
dian Cardiovascular Society; CCU: Coronary care unit;
CES-D: Centre for Epidemiological Studies - Depression
Scale; CHD: Coronary heart disease; CHD-PHARM/
Control: Community pharmacy-led medicines manage-
ment programme/control treatment for patients with
CHD; CML: Case method learning supported lipid-low-
ering strategy; COMM - CVD/NOCVD: Community
dwelling-based elderly patients with/without CVD; CR:
Cardiac resynchronisation; CR-Home/Hosp: Home/Hos-
pital-based cardiac rehabilitation; C-REHAB: Cardiac
rehabilitation; CS: Conservative strategy; CVA: Cerebro-
vascular Accident; CVD: Cardiovascular disease; Duplex
US: Duplex ultrasonography; Echo: Echocardiography;
EHS-CR: Euro Heart Survey on coronary revascularisa-
tion; Endo: Endovascular AAA surgery; ES: Effect size;
Exercise-Qol: Long-term effects of exercise training on
quality of life; F-u: Follow-up; GRS: Guyatt’s responsive-
ness statistic; HeartMed: Lifestyle advice intervention by
community pharmacists for heart failure patients; HF:
Heart failure; HOSP - CVD: Hospital-based elderly
patients with CVD; HRQoL: Health-related quality of
life; HUI2/3: Health Utilities Index mark 2/3; IC: Inter-
mittent claudication; ICC: Intra-class correlation; ICD:
Implantable cardioverter defibrillator; ICP: Integrated
care pathway; IHD: Ischaemic heart disease; IQR: Inter-
quartile range; IS: Interventional strategy; IV: Intrave-
nous; KCCQ: Kansas City Cardiomyopathy Question-
naire; LV: Left ventricular; MacNew: MacNew Heart
Disease Quality of Life Questionnaire; MCS: Mental
component summary; MDT: Multi-disciplinary team;
MEDMAN: Community pharmacy-led medicines man-
agement services; MEPS: Medical expenditure panel
survey; MI: Myocardial infarction; MI - Self-help:
Home-based self-help rehabilitation package for MI
patients; MIDCAB: Minimally invasive direct CABG;
MM: Medical management; MR Angio: Magnetic reso-
nance angiography; MRI: Magnetic resonance imaging;
MT: Medical therapy; MVPS: Mitral valve prolapse syn-
drome; NYHA: New York Heart Association; OP-
CABG: Off-pump CABG; Open: Open AAA surgery;
PAOD: Peripheral arterial occlusive disease; PCI: Percu-
taneous coronary intervention; PCI-BMS: PCI with
bare-metal stents; PCI-CABG/MM/PCI: Patients who
are suitable for PCI and receive CABG/PCI/MM; PCI-
DES: PCI with drug-eluting stents; PCS: Physical com-
ponent summary; PER: Peripheral endovascular revascu-
larisation; Pre-op: Pre-operation; Proxy: HRQol
questionnaire completed by spouse/family member;
PSM: Patient self-management; P-PTCA: Primary
PTCA; P-Stent: Primary stent placement; PTCA: Percu-
taneous transluminal coronary angioplasty; QLMI: Qual-
ity of Life after MI questionnaire; QoL: Quality of life;
RCT: Randomised controlled trial; REV/NO REV: Eligi-
ble/Ineligible for Revascularisation; SAH: Subarachnoid
haemorrhage; SCOPE-Drug/Control: Study on cognition
and prognosis in the elderly - Drug/Control treatment;
SD: Standard deviation; SES: Socioeconomic status; SF-
36: Short-form 36-item health survey questionnaire; SF-
6D: Short-form 6D; SF-12: Short-form 12-item health
survey questionnaire; SPECT: Single photon emission
computed tomography; SRM: Standardised response
means; Stroke-4Y: Four years post-stroke; TIA: Trans-
ischaemic attack; Trans.: Heart Transplantation; Tx:
Treatment; UC: Usual care; VAD: Ventricular assist
device; VAS: Visual analogue scale; VascuQol: Vascular
Quality of Life Questionnaire; -ve/+ve: Deterioration/
Improvement in condition; WHO-ICD: World Health
Organisation - International Classification of Diseases;
W-list: Waiting-list.
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Additional file 1: Tables. Table 1: Description of studies that have used
the EQ-5D as an outcome measure in clinical and observational studies
of patients with cardiovascular disease. Table 2: Summary of studies
examining validity and reliability of EQ-5D in cardiovascular disease (n =
10). Table 3: Summary of EQ-5D utility scores reported in cardiovascular
studies. Table 4: Canadian Cardiovascular Society (CCS) and New York
Heart Association (NYHA) classification systems [53-95].
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1477-7525-8-13-
S1.DOC ]
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